Prostatic-specific Antigen Velocity After Holmium Laser Enucleation of the Prostate: Possible Predictor for the Assessment of Treatment Effect Durability for Benign Prostatic Hyperplasia and Detection of Malignancy

Urology

Volumn 74, Issue 5, 2009, Pages 1105-1110

  Elmansy, Hazem M ^a   Elzayat, Ehab A ^a   Sampalis, John S ^a   Elhilali, Mostafa M ^a  

^a Faculty of Medicine   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; HOLMIUM LASER; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

AGED; HUMANS; LASER THERAPY; LASERS, SOLID-STATE; LONGITUDINAL STUDIES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 70350574639     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.06.039     Document Type: Article

References (24)

1. 3. Urology 73 (2009) 95-99
2. Kuntz R.M., Lehrich K., and Ahyai S.A. Holmium laser enucleation of the prostate versus open prostatectomy for prostate greater than 100 grams: 5 year follow up results of a randomized clinical trial. Eur Urol 53 (2008) 160-168
3. Peterson M.D., Matlaqa B.R., Kim S.C., et al. Holmium laser enucleation of the prostate for men with urinary retention. J Urol 174 (2005) 998-1001
4. Elzayat E.A., and Elhilali M.M. Holmium laser enucleation of the prostate (HoLEP): long-term results, reoperation rate and possible impact of the learning curve. Eur Urol 52 (2007) 1465-1472
5. Tinmouth W.W., Habib E., Kim S.C., et al. Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection?. J Endourol 19 (2005) 550-554
6. Shingleton W.B., Terrell F., Kolski J., et al. Prostate specific antigen measurements after minimally invasive surgery of the prostate in men with benign prostatic hypertrophy. Prostate Cancer Prostatic Dis 3 (2000) 200-202
7. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J Am Med Assoc 267 (1992) 2215-2220
8. Fang J., Metter E.J., Landis P., et al. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 59 (2002) 889-893
9. Loeb S., Roehl K.A., Catalona W.J., et al. PSA velocity threshold for predicting prostate cancer in young men. J Urol 177 (2007) 899-902
10. Raaijmakers R., Wildhagen M.F., Ito K., et al. Prostate-specific antigen change in the European randomized study of screening for prostate cancer, section Rotterdam. Urology 63 (2004) 316-320
11. Roobol M.J., Kranse R., de Koning H.J., et al. Prostate-specific antigen velocity at low prostate -specific levels as screening tool for prostate cancer: result of second screening round of ERSPC (Rotterdam). Urology 63 (2004) 309-313
12. Schroder F.H., Roobol M.J., Van der Kwast T.H., et al. Does PSA velocity predict prostate cancer in pre-screened population?. Eur Urol 49 (2006) 460-465
13. Smith D.S., and Catalona W.J. Rate of changes in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 152 (1994) 1163-1167
14. Berger A.P., Deibl M., Steiner H., et al. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 64 (2005) 240-245
15. Connolly D., Black A., Murray L.J., et al. Methods of calculating prostate-specific antigen velocity. Eur Urol 52 (2006) 1044-1051
16. Yu X., Han M., Loeb S., et al. Comparison of methods for calculating prostate specific antigen velocity. Oncology 176 (2006) 2427-2431
17. Fong B.C., and Elhilali M.M. Video article. Ho: YAG laser enucleation of the prostate: technical details. BJU Int 90 (2002) 870-871
18. El-Hakim A., and Elhilali M.M. Holmium laser enucleation of the prostate can be taught: the first learning experience. BJU Int 90 (2002) 863-869
19. Stamey T.A., Yang N., Hay A.R., et al. Prostatic serum antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909-916
20. Aus G., Bergdahl S., Frosing R., et al. Reference range of prostatic specific antigen after transurethral resection of the prostate. Urology 47 (1996) 529-531
21. Hai M.A., and Malek R.S. Photoselective vaporization of the prostate: initial experience of a new 80 W KTP laser for the treatment of benign prostatic hyperplasia. J Endourol 17 (2003) 93-96
22. Te A.E., Malloy T.R., Stein B.S., et al. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicenter study at 3 years. BJU Int 97 (2006) 1229-1233
23. Zlotta A.R., Giannakopoulos X., Maehlum O., et al. Long term evaluation of transurethral needle ablation of the prostate(TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 44 (2003) 89-93
24. Marks L.S., Dorey F.J., Rhodes T., et al. Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. J Urol 156 (1996) 1035-1038